WHWK

Whitehawk Therapeutics, Inc. WHWK

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,729 of 3,064

Why it scores 26Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$0

Quarter to Jun 30

Net income

$-16.64M

Quarter to Jun 30

Free cash flow

$-14.53M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$198.03M total
Yu Fan
$22.26M+134.8%
ACUTA CAPITAL PARTNERS, LLC
$21.46M+37.4%
QVT Financial LP
$21.14M0.0%
SUVRETTA CAPITAL MANAGEMENT, LLC
$19.69M+16.2%
ORBIMED ADVISORS LLC
$18.02M-5.6%
Avoro Capital Advisors LLC
$13.05M0.0%
Siren, L.L.C.
$10.70M+12.3%
KVP Capital Advisors, LP
$9.92M0.0%
BlackRock, Inc.
$8.81M+447.2%
VANGUARD CAPITAL MANAGEMENT LLC
$6.36M+5.5%
ADAR1 Capital Management, LLC
$6.14M+943.9%
ACORN CAPITAL ADVISORS, LLC
$5.22M0.0%
StemPoint Capital LP
$4.68M+8.7%
GEODE CAPITAL MANAGEMENT, LLC
$4.12M+96.7%
Ally Bridge Group (NY) LLC
$3.75M0.0%
Woodline Partners LP
$2.00M+55.1%
RENAISSANCE TECHNOLOGIES LLC
$1.90M-3.5%
STATE STREET CORP
$1.77M+141.3%
MILLENNIUM MANAGEMENT LLC
$1.74M+22.8%
Eversept Partners, LP
$1.39M-1.1%
Verdad Advisers, LP
$1.38M+161.1%
TWO SIGMA INVESTMENTS, LP
$1.36M+8.5%
BALYASNY ASSET MANAGEMENT L.P.
$1.32M-47.7%
NORTHERN TRUST CORP
$1.21M+146.8%
VANGUARD FIDUCIARY TRUST CO
$1.13M+14.9%
See all 78 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/WHWK

Earnings Per Share

13fpro.ai/company/WHWK

Loading ratio trend…

WHWK key financials by period

Reported revenue, net income and operating margin by fiscal year, from Whitehawk Therapeutics, Inc.'s annual filings on SEC EDGAR.

Whitehawk Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$7.1M$-20.6M—
FY 2024$26.0M$-63.7M—
FY 2023$24.4M$-65.8M—
FY 2022$15.2M$-60.5M—
FY 2021$14.0M$-110.1M—
FY 2020$14.0M$-3.5M-18.2%
Source: WHWK filings on SEC EDGAR →

WHWK insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Whitehawk Therapeutics, Inc. (WHWK): stock profile, AI score and financials

Whitehawk Therapeutics, Inc. (WHWK) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores WHWK at 26.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,729 of 3,064 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (3.3) and earnings quality (16.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Whitehawk Therapeutics, Inc. reports net income of $-16.6M, free cash flow of $-14.5M. Top institutional holders of WHWK by reported 13-F value include Yu Fan, ACUTA CAPITAL PARTNERS, QVT Financial, based on the most recent SEC filings. WHWK trades on the Nasdaq exchange and files with the SEC under CIK 1422142. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate WHWK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Whitehawk Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1422142 →